Dr Himesh Gandhi, Consultant Uro-oncologist and Director of Robotic Surgery at Ruby Hall Clinic, highlights how Ruby Hall Clinic’s new Focal One Robotic HIFU system targets only cancerous prostate tissue, sparing healthy areas to minimize incontinence and erectile dysfunction. This precision therapy offers day-care procedures and rapid recovery for India’s rising prostate cancer cases, bridging the gap between overtreatment and undertreatment.
The conversation around prostate cancer is changing and rightfully so. For decades, the focus has been on survival at any cost, often overlooking what that survival looks like for the patient. Today, as we see a steady rise in Prostate Cancer across India, there is a growing need to rethink not just how we treat the disease, but how we preserve quality of life alongside it.
It is in this context that the introduction of the Focal One Robotic HIFU system at Ruby Hall Clinic becomes particularly significant. This is not just the adoption of a new technology; it is a shift in philosophy.
Moving Beyond Radical Treatment
Traditionally, prostate cancer management has relied on radical interventions, complete removal of the prostate or full-gland radiation therapy. While these treatments have undoubtedly saved lives, they often come at a cost. Urinary incontinence, erectile dysfunction, and long recovery periods are not uncommon, and for many patients, these side effects can be life-altering.
In clinical practice, one of the most difficult conversations is with a patient who has localized disease but is hesitant to undergo surgery because of these potential complications. Equally challenging are cases where patients opt for active surveillance but live with constant anxiety about disease progression.
This gap between overtreatment and undertreatment is where focal therapy has emerged as a meaningful alternative.
The Science of Precision: What Makes HIFU Different
High-Intensity Focused Ultrasound (HIFU) represents a fundamentally different approach. Instead of removing or irradiating the entire prostate, HIFU allows us to target only the cancerous tissue with high precision.
The technology works by focusing ultrasound waves onto a specific area within the prostate. At the focal point, temperatures rise rapidly, leading to the destruction of cancer cells while sparing surrounding healthy structures. There are no incisions, no radiation exposure, and minimal disruption to adjacent tissues.
What elevates this approach further is the integration of robotics and advanced imaging in the Focal One system. By combining MRI data with real-time ultrasound, we can map the prostate in three dimensions, identify the exact location of the tumor, and treat it with sub-millimetric accuracy.
For the clinician, this translates into control and confidence. For the patient, it means a treatment that is both effective and less invasive.
A Shift Towards Personalised Cancer Care
No two prostate cancers are the same and neither should their treatment be. One of the most compelling aspects of focal HIFU is its ability to personalise therapy.
Instead of treating the entire gland, we can now tailor the intervention to the disease itself, treating only the affected area while preserving the rest of the prostate. This organ-preserving approach is particularly valuable in patients with localized or intermediate-risk disease, where the goal is not just cure, but also functional preservation.
In many ways, this represents a broader shift in oncology from a one-size-fits-all model to a more nuanced, patient-centric approach.
The Ruby Hall Clinic Milestone
The introduction of the Focal One Robotic HIFU system at Ruby Hall Clinic is a landmark development in this journey. It places the institution among a select group of centres globally that offer robotic, image-guided focal therapy for prostate cancer.
More importantly, it expands the spectrum of treatment options available to patients in India, particularly those who may not be ideal candidates for surgery or who are seeking less invasive alternatives.
From a clinical standpoint, the benefits are significant. The procedure is typically performed as a day-care intervention, recovery is rapid, and the risk of major complications is considerably lower compared to conventional treatments. Additionally, the ability to repeat the procedure, if necessary, offers flexibility that is not always possible with other modalities.
Addressing the Indian Context
In India, prostate cancer often presents unique challenges. Awareness remains limited, screening is not uniformly practiced, and many patients present at a stage where treatment decisions become more complex.
Equally important is the cultural context, where concerns around quality of life, particularly urinary and sexual function, are often under-discussed but deeply impactful.
Technologies like HIFU have the potential to bridge this gap. By offering a treatment that is effective yet less disruptive, we can encourage more patients to come forward earlier and consider timely intervention.
Looking Ahead
The future of prostate cancer care lies in precision, preservation, and personalisation. While long-term data on focal therapies continues to evolve, the current evidence is promising, particularly in carefully selected patients.
As clinicians, our goal is not just to treat disease, but to treat the individual to balance oncological control with quality of life. The integration of technologies like robotic HIFU allows us to move closer to that ideal.
Conclusion
The launch of the Focal One Robotic HIFU system at Ruby Hall Clinic marks an important step forward in this direction. It is a reminder that progress in medicine is not only about doing more, but about doing better. And in the case of prostate cancer, doing better means treating effectively while preserving the dignity and quality of life of every patient we care for.
